摘要
目的探讨孟鲁司特钠片联合布地奈德鼻喷雾剂对过敏性鼻炎的治疗效果。方法 98例过敏性鼻炎患儿,随机分为对照组和观察组,每组49例。对照组单纯使用布地奈德鼻喷雾剂治疗,观察组采取孟鲁司特钠片联合布地奈德鼻喷雾剂治疗,比较两组患儿白细胞介素6(IL-6)、白细胞介素8(IL-8)、白细胞介素10(IL-10)水平以及生活质量评分。结果观察组患儿IL-6(102.54±10.28)ng/L、IL-8(105.22±11.72)ng/L显著低于对照组的(146.48±12.55)ng/L、(135.77±12.31)ng/L,IL-10(17.58±2.61)ng/L明显高于对照组的(13.65±1.55)ng/L,差异具有统计学意义(P<0.05)。观察组患儿的生活质量(情感反应、活动与行为、睡眠质量、眼鼻症状、非眼鼻症状)评分显著低于对照组,差异具有统计学意义(P<0.05)。结论采用孟鲁司特钠片联合布地奈德鼻喷雾剂治疗过敏性鼻炎具有较好效果,可以显著改善生活质量,值得临床推广应用。
Objective To investigate the treatment effect of Montelukast Sodium Tablets combined with Budesonide nasal spray in the treatment of allergic rhinitis. Methods A total of 98 children with allergic rhinitis were randomly divided into control group and observation group, 49 cases in each group. The control group was treated with Budesonide nasal spray alone, the observation group was treated with Montelukast Sodium Tabletscombined with Budesonide nasal spray. The levels of Interleukin-6(IL-6), Interleukin-8(IL-8), Interleukin-10(IL-10) and quality of life score between the two groups were compared. Results The levels of IL-6 and IL-8 in the observation group were(102.54±10.28) ng/L and(105.22±11.72) ng/L respectively, which were significantly lower than(146.48±12.55) ng/L and(135.77±12.31) ng/L in the control group, the level of IL-10 in the observation group was(17.58±2.61) ng/L, which was significantly higher than(13.65±1.55) ng/L in the control group, the differences were statistically significant(P〈0.05). The quality of life(emotional reaction, activity and behavior, sleep quality, eye and nose symptoms, non-eye and nose symptoms) scores of the observation group were significantly lower than those of the control group, the differences were statistically significant(P〈0.05). Conclusion Montelukast Sodium Tablets combined with Budesonide nasal spray in the treatment of allergic rhinitis has a better effect, can significantly improve the quality of life, is worthy of clinical promotion and application.Key words
作者
汪桂美
WANG Gui-rnei(The People's Hospital of Huidong County,Huidong 516300,China)
出处
《中国现代药物应用》
2018年第17期80-82,共3页
Chinese Journal of Modern Drug Application